期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 66, 期 10, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00745-22
关键词
MRSA; ceftaroline; health care associated; resistance; pediatric; invasive; mecR
资金
- Agency for Healthcare Research and Quality [AHRQ R01HS026896]
- NIAID [R01AI25216, R21AI153663, R21AI142126, R21AI59059]
- Pfizer
Ceftaroline is a promising therapy option for MRSA infections in pediatric patients. However, there is limited data on the frequency of ceftaroline resistance in this population. A study conducted at a tertiary children's hospital found that 2.9% of invasive MRSA isolates were resistant to ceftaroline, and this resistance was only observed in healthcare-associated infections. The resistant isolates were more often resistant to clindamycin, and sequencing data revealed the predominance of the CC5 lineage among the ceftaroline-resistant isolates.
Ceftaroline represents an attractive therapy option for methicillin-resistant Staphylococcus aureus (MRSA). Little data is available, however, regarding the frequency of reduced susceptibility (RS) to ceftaroline among pediatric MRSA infections. We screened invasive MRSA isolates at a tertiary children's hospital for ceftaroline RS. Ceftaroline RS occurred in 2.9% of isolates and only among health care associated infections. Ceftaroline RS isolates were more often clindamycin-resistant. Sequencing data indicated the predominance of the CC5 lineage among ceftaroline RS isolates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据